| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
25,227 |
22,632 |
$4.30M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
30,031 |
27,317 |
$3.86M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
79,395 |
59,542 |
$2.61M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
16,430 |
14,958 |
$1.39M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
28,512 |
24,484 |
$1.36M |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
8,704 |
6,665 |
$728K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
21,501 |
18,766 |
$611K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
7,037 |
4,860 |
$521K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
16,618 |
13,898 |
$458K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
1,364 |
1,193 |
$400K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
5,271 |
3,377 |
$391K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,984 |
1,004 |
$380K |
| 59025 |
Fetal non-stress test |
1,729 |
815 |
$274K |
| 71045 |
Radiologic examination, chest; single view |
9,369 |
8,395 |
$232K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
6,106 |
5,561 |
$221K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
9,913 |
8,111 |
$188K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,524 |
5,130 |
$174K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
36,487 |
30,227 |
$168K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
6,027 |
4,765 |
$155K |
| 80053 |
Comprehensive metabolic panel |
23,019 |
18,325 |
$137K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,565 |
1,226 |
$134K |
| 81025 |
|
21,308 |
18,835 |
$129K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
2,136 |
1,821 |
$115K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
157 |
131 |
$106K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,701 |
1,003 |
$101K |
| 99215 |
Prolong outpt/office vis |
2,176 |
1,795 |
$92K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
6,329 |
4,761 |
$88K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
860 |
704 |
$85K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,184 |
1,089 |
$83K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,000 |
2,582 |
$79K |
| 80047 |
|
11,506 |
10,280 |
$77K |
| 36415 |
Collection of venous blood by venipuncture |
45,259 |
35,342 |
$74K |
| 84484 |
|
12,053 |
9,357 |
$71K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
280 |
211 |
$54K |
| 0002A |
|
1,347 |
1,188 |
$43K |
| 0001A |
|
1,368 |
1,259 |
$41K |
| 76801 |
|
544 |
403 |
$41K |
| 71046 |
Radiologic examination, chest; 2 views |
685 |
620 |
$35K |
| 81001 |
|
15,071 |
13,393 |
$33K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
57 |
44 |
$33K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
101 |
94 |
$28K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
1,160 |
702 |
$27K |
| 76818 |
|
570 |
404 |
$26K |
| 80076 |
|
5,066 |
4,516 |
$24K |
| 83880 |
|
1,410 |
1,277 |
$23K |
| 70450 |
Computed tomography, head or brain; without contrast material |
168 |
159 |
$21K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
585 |
472 |
$18K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
761 |
207 |
$18K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
122 |
119 |
$18K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
185 |
167 |
$18K |
| 83690 |
|
3,051 |
2,689 |
$13K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,239 |
1,971 |
$12K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
259 |
235 |
$12K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
126 |
118 |
$12K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
177 |
120 |
$10K |
| 81003 |
|
5,787 |
4,512 |
$10K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
47 |
42 |
$9K |
| 0004A |
|
260 |
221 |
$9K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
297 |
268 |
$8K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
158 |
132 |
$8K |
| 51705 |
|
143 |
93 |
$8K |
| 76820 |
|
96 |
43 |
$7K |
| 85027 |
|
2,075 |
1,826 |
$7K |
| G0378 |
Hospital observation service, per hour |
92 |
38 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,120 |
1,737 |
$7K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
27 |
24 |
$7K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
308 |
290 |
$6K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
121 |
113 |
$6K |
| 90715 |
|
371 |
331 |
$6K |
| 82550 |
|
1,928 |
1,709 |
$6K |
| 83735 |
|
1,759 |
1,209 |
$6K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
57 |
53 |
$4K |
| 19301 |
|
14 |
12 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,092 |
925 |
$3K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
231 |
220 |
$3K |
| 82962 |
|
1,418 |
1,208 |
$3K |
| 73562 |
|
59 |
53 |
$3K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
524 |
447 |
$3K |
| 83615 |
|
801 |
677 |
$2K |
| 73120 |
|
47 |
24 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
74 |
65 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
74 |
65 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,325 |
1,097 |
$2K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
451 |
319 |
$2K |
| 90674 |
|
333 |
290 |
$2K |
| 94060 |
|
27 |
24 |
$2K |
| 76641 |
|
31 |
29 |
$2K |
| 93296 |
|
531 |
478 |
$2K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
42 |
36 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
124 |
117 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,379 |
1,111 |
$1K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
4,921 |
1,652 |
$1K |
| 85730 |
|
493 |
431 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
676 |
601 |
$1K |
| 0003A |
|
41 |
32 |
$1K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
2,329 |
1,864 |
$1K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
28 |
25 |
$1K |
| 94729 |
|
27 |
24 |
$1K |
| 85014 |
|
857 |
747 |
$1K |
| 85610 |
|
534 |
463 |
$1K |
| 97161 |
|
26 |
24 |
$968.24 |
| 87070 |
|
119 |
112 |
$934.18 |
| 82248 |
|
330 |
290 |
$862.32 |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
227 |
203 |
$800.22 |
| 83970 |
|
29 |
27 |
$743.04 |
| 94726 |
|
14 |
12 |
$739.20 |
| 83605 |
|
140 |
114 |
$733.62 |
| 74022 |
|
14 |
13 |
$729.68 |
| 87210 |
|
166 |
151 |
$726.44 |
| 73610 |
|
14 |
12 |
$718.70 |
| 96523 |
|
63 |
52 |
$702.97 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
33 |
29 |
$667.00 |
| 80069 |
|
97 |
90 |
$581.56 |
| 86710 |
|
63 |
52 |
$526.37 |
| 82947 |
|
103 |
89 |
$524.50 |
| 73630 |
|
14 |
12 |
$474.72 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
17 |
15 |
$434.79 |
| 90686 |
|
48 |
47 |
$429.19 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
56 |
55 |
$398.13 |
| 80061 |
Lipid panel |
38 |
36 |
$374.92 |
| 84443 |
Thyroid stimulating hormone (TSH) |
29 |
26 |
$372.34 |
| 82728 |
|
44 |
40 |
$368.01 |
| 84702 |
|
34 |
27 |
$346.15 |
| 82570 |
|
62 |
58 |
$336.70 |
| 73030 |
|
13 |
12 |
$316.84 |
| 97602 |
|
37 |
29 |
$300.03 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
17 |
15 |
$296.00 |
| 82553 |
|
50 |
37 |
$284.76 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
234 |
196 |
$278.61 |
| 84153 |
|
36 |
27 |
$239.07 |
| 87400 |
|
46 |
40 |
$237.07 |
| 82043 |
|
62 |
58 |
$236.98 |
| 83550 |
|
43 |
39 |
$235.98 |
| 93298 |
|
106 |
84 |
$228.79 |
| 83540 |
|
44 |
40 |
$171.18 |
| 84100 |
|
58 |
44 |
$161.16 |
| 87430 |
|
14 |
13 |
$159.50 |
| 80348 |
|
12 |
12 |
$127.74 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
13 |
12 |
$122.51 |
| 84156 |
|
44 |
40 |
$106.43 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
20 |
13 |
$91.41 |
| 81002 |
|
29 |
27 |
$85.50 |
| J0173 |
Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg |
49 |
39 |
$85.04 |
| 87081 |
|
14 |
13 |
$80.96 |
| 91300 |
|
3,356 |
2,497 |
$73.39 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
18 |
13 |
$72.84 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
13 |
12 |
$66.01 |
| J2704 |
Injection, propofol, 10 mg |
1,189 |
1,008 |
$58.65 |
| 85018 |
|
24 |
24 |
$51.71 |
| A6197 |
Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing |
22 |
14 |
$51.20 |
| 90661 |
|
21 |
20 |
$50.85 |
| 94799 |
|
315 |
96 |
$31.80 |
| 99152 |
|
14 |
12 |
$31.35 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
167 |
144 |
$24.44 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
17 |
13 |
$23.20 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
206 |
176 |
$15.73 |
| J7050 |
Infusion, normal saline solution, 250 cc |
67 |
55 |
$15.68 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
21 |
18 |
$10.56 |
| J2060 |
Injection, lorazepam, 2 mg |
15 |
13 |
$8.99 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
17 |
17 |
$3.32 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
26 |
24 |
$3.11 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,457 |
1,344 |
$0.00 |
| 99001 |
|
109 |
93 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
110 |
66 |
$0.00 |
| V2787 |
Astigmatism correcting function of intraocular lens |
39 |
12 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
38 |
30 |
$0.00 |
| 76098 |
|
15 |
14 |
$0.00 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
16 |
12 |
$0.00 |
| 93798 |
|
77 |
12 |
$0.00 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,455 |
944 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
76 |
71 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
194 |
169 |
$0.00 |
| C9290 |
Injection, bupivacaine liposome, 1 mg |
58 |
53 |
$0.00 |
| V2632 |
Posterior chamber intraocular lens |
15 |
14 |
$0.00 |
| 91305 |
|
12 |
12 |
$0.00 |